Mometasone Furoate Market Size, Share, Growth, Trends, and Global Industry Analysis: By Dosage Form (Nasal Spray, cream, Ointment, Inhalers, Others), By Indications (Inflammatory Skin Disorder, Asthma, Allergic Rhinitis Others), By Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Others), and Region Forecast 2020-2031

Mometasone Furoate Market size was valued at US$ 1,020 million in 2024 and is expected to reach US$ 1,390 million by 2031, growing at a significant CAGR of 3.6% from 2025-2031. Moreover, the U.S. Mometasone Furoate Market is expected to grow significantly, reaching an estimated value of US$ 540 million by 2031, driven by rising cases of asthma, allergic rhinitis, and demand for topical corticosteroids. The worldwide market is slowly gaining momentum driven by its wide clinical use in the treatment of dermatologic, respiratory, and allergic diseases. As an effective corticosteroid drug possessing anti-inflammatory and anti-pruritic properties, Mometasone Furoate is a drug of preference in the management of asthma, allergic rhinitis, and other conditions like eczema and psoriasis.

The increasing incidence of allergic disease, compound by pollution, urbanization, and climatic uncertainty, has provided a new need for long-term and effective corticosteroid treatment. Its good safety profile and preference for a once-daily dose has positioned it as the first choice among clinicians, and therefore it is prescribed as a first-line drug among paediatric and adult patients in chronic diseases.

Also, increasing generic production and expanding awareness of topical corticosteroids among emerging economies is transforming market dynamics. Pharmaceuticals are making increasing investments in new forms of delivery like inhalers, nasal sprays, and topical versions in order to expand the therapeutic use of Mometasone Furoate and differentiate products in an overlapping market. Research into combination therapy, particularly within respiratory medicine, is also likely to drive increased utilization. With demand increasing via prescription and over-the-counter channels both, and regulatory approvals becoming more streamlined, Mometasone Furoate is set to redefine its market from a mature category to a more innovation-focussed and globally diversified market.

Key Developments:

• In May 2025, MSD Animal Health gained FDA approval for MOMETAMAX SINGLE™, a single-dose otic suspension of gentamicin, posaconazole, and mometasone furoate, for the treatment of canine otitis externa. The product will be available in U.S. veterinary clinics during summer 2025, expanding mometasone's reach in veterinary medicine.
• In May 2024, Aurobindo Pharma had received approval to distribute and make Mometasone Furoate Monohydrate Nasal Spray, a bioequivalent of Organon LLC's Nasonex. The medication is used to treat perennial and seasonal allergic rhinitis and will be launched during Q1 FY25 to further reach the U.S. generics market.
• In May 2021, Glenmark Pharmaceuticals launched Ryaltris-AZ Nasal Spray, an antihistamine combination with mometasone furoate in May 2021. For patients above 12 years old with allergic rhinitis, the spray targets both nasal and ocular manifestations, highlighting innovation in dual-action therapy.

Mometasone Furoate Market Segmentation:

Based on the dosage form:

• Nasal Spray
• Cream
• Ointment
• Inhales
• Others

Nasal spray is a leading dosage form in the market due to its efficacy in the management of allergic rhinitis and sinusitis. The route of administration has localized action with minimal systemic exposure, which can be employed either for seasonal or long-term use. Its non-invasive nature and rapid onset of action render it the physician's and patient's top choice, especially among pediatric and elderly patients. Owing to allergic rhinitis becoming common in urban communities, nasal sprays are increasingly becoming a favorite option in prescription and over-the-counter categories. Preservative-free and metered-dose formulations are also being made by drug companies, enhancing compliance and gaining market share in the respiratory segment.

Based on the indication:

• Inflammatory Skin Disorder
• Asthma
• Allergic rhinitis
• Others

Asthma represents a principal therapeutic indication driving demand for Mometasone Furoate, particularly through inhalation-based therapy. Prevention of asthma exacerbation and reduction of airway swelling are the mechanisms of action in the drug and thus represent the key therapy for the control of long-term disease. Strong safety profiles enable use in children and adults, most commonly maintenance therapy in combination with long-acting bronchodilators. With the rising worldwide burden of asthma, caused by air pollution, allergens, and genetics, there is consistent demand for inhaled corticosteroids like Mometasone. Global guidelines like GINA increasingly are advising its use as part of stepwise asthma control regimens, leading to steady uptake and inducing formulation advances aimed at improving adherence and delivery precision.

Based on the distribution channel:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Retail pharmacies dominate the distribution channel for Mometasone Furoate-formulated products, particularly for nasal sprays and topical products sold over the counter or through prescription. Their accessibility and wide reach make them the preferred channel for patients seeking immediate and convenient relief from allergies, asthma, or skin conditions. Pharmacists are also a source of guidance for the right product choice and usage, especially in parts of the country where clinical access is limited. Chain pharmacy outlets and web-based pharmacy sites are also helping enhance distribution efficiency and availability of the product. As more branded generics and consumer-friendly versions arrive on the shelves, retail pharmacies continue to be an essential way to deliver the molecule to the urban and semi-urban masses.